By Fineline Cube China’s National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines—the Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition) and the Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)—alongside a draft announcement proposing significant optimizations to the review and approval process for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.
Regulatory Framework Overview
| Document | Key Purpose | Status |
|---|---|---|
| Cell Therapy Guideline (2026) | Defines scope, classification, and exclusions for CTMPs | Effective immediately |
| Gene Therapy Guideline (2026) | Establishes clear parameters for GTMP definition and categorization | Effective immediately |
| CGT Review Optimization Announcement | Proposes expedited pathways and support mechanisms for CGT development | Draft for public comment |
Cell Therapy Medicinal Products (CTMPs) – Definition & Classification
Core Definition
CTMPs are defined as drugs that:
- Use human cells, tissues, or body fluids as starting raw materials
- Are manufactured through ex vivo manipulation
- Have cells as the active ingredient
- Achieve intended use through mechanisms including:
- Regulating biological activity, immunological properties, or metabolic status of cells
- In vivo cell replacement, regeneration, and functional reconstruction
Classification System
- Non-genetically modified CTMPs: No genetic material alteration during ex vivo manipulation
- Ex vivo genetically modified CTMPs: Genetic modification occurs during manufacturing process
Explicit Exclusions
- Blood components for transfusion derived from blood collection
- Unprocessed human cells, tissues, or organs for transplantation
- Artificial embryos and germ cells used in reproductive technologies
Gene Therapy Medicinal Products (GTMPs) – Definition & Classification
Core Definition
GTMPs are defined as drugs that achieve intended use by:
- Introducing exogenous gene sequences via nucleic acids (DNA/RNA)
- Using viral or non-viral vectors for delivery
- Employing nucleases/proteases acting on specific genes
- Specifically altering gene sequences or regulating gene expression through:
- Replacement, compensation, blockade, correction, or silencing of specific genes
Classification System
- Non-microbial vector-based GTMPs: Utilize non-viral delivery systems
- Microbial vector-based GTMPs: Employ viral or other microbial vectors
Explicit Exclusions
- Prophylactic vaccines
- Chemically synthesized oligonucleotide drugs
Review & Approval Optimization Measures
| Initiative | Benefit | Timeline/Details |
|---|---|---|
| 30-Day Clinical Trial Channel | Expedited IND review for eligible CGT products | 30-day review timeline vs. standard |
| Full-Process Guidance Services | Enhanced CDE support for high-value CGT candidates | Type I meeting communication, pre-receiving assistance |
| Priority Review & Approval | Accelerated marketing application review | For products with new targets, mechanisms, or significant clinical value |
| Manufacturing Process Change Review | Faster approval for post-marketing manufacturing upgrades | 130 working days (reduced from 200 working days) |
Strategic Focus Areas for CGT Development
The NMPA explicitly encourages R&D investment in:
- Malignant tumors
- Rare diseases
- Genetic disorders
- Immune system diseases
- Neurodegenerative diseases
Additional incentives include support for global simultaneous R&D and international multi-center clinical trials conducted in China.
Market Impact & Industry Implications
- Regulatory Clarity: The guidelines eliminate previous ambiguities around CGT product definitions, providing clear boundaries for developers
- Competitive Advantage: Chinese CGT companies gain predictable regulatory pathways comparable to FDA and EMA frameworks
- Investment Attraction: Streamlined review timelines and priority programs make China an attractive jurisdiction for global CGT development
- Innovation Catalyst: The 30-day clinical trial channel could accelerate first-in-human studies by 60-70% compared to standard timelines
- Manufacturing Flexibility: Reduced review time for process changes addresses a key industry pain point in CGT commercial-scale manufacturing
The comprehensive regulatory package positions China as a leading destination for cell and gene therapy innovation, with clear definitions, accelerated pathways, and targeted support for high-impact therapeutic areas.-Fineline Info & Tech